Skip to content
Triangle logo TriangleGet started
← Study library

NCT01154816 · REGISTRY CONDITION SEARCH

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2020-05-13

This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Overall Response

→

outcome · POSTED

Number of Patients Cycles With Grade 3 or Higher Adverse Event

→

outcome · POSTED

Serum Concentration of Alisertib Prior to the First Day of Administration

→

outcome · POSTED

Serum Concentration of Alisertib on the First Day of Administration One Hour After Administration

→

outcome · POSTED

Serum Concentration of Alisertib on the First Day of Administration Three Hours After Administration

→

outcome · POSTED

Serum Concentration of Alisertib on the First Day of Administration Six Hours After Administration

→

outcome · POSTED

Serum Concentration of Alisertib on the Fourth Day of Administration Prior to the Administration of the Day 4 Dose

→

outcome · POSTED

Serum Concentration of Alisertib on the Seventh Day of Administration Prior to the Administration of the Day 7 Dose.

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have had histologic verification of malignancy at original diagnosis or at relapse, to include any of the following malignancies (no other histology is eligible): * Neuroblastoma- measurable * Neuroblastoma- MIBG evaluable * Rhabdomyosarcoma * Osteosarcoma * Ewing sarcoma/Peripheral PNET * Non-RMS soft tissue sarcoma * Hepatoblastoma * Malignant germ cell tumor * Wilms tumor * Acute lymphoblastic leukemia * Acute myelogenous leukemia * Rhabdoid malignancy * Disease status for solid tumor patients: * Patients must have radiographically measurable disease (with the exception of neuroblastoma) * Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 20 mm in at least one dimension; for spiral CT, measurable disease is defined as a minimum diameter of 10 mm in at least one dimension * Note: The following do not qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions) * Bone marrow infiltration * Lesions detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) * Elevated tumor markers in plasma or cerebrospinal fluid (CSF) * Previously irradiated lesions that have not demonstrated clear progression post radiation * Patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible * Disease status for leukemia patients: * Patients with leukemia must be recurrent or refractory to at least two prior induction or treatment regimens, in addition to the following criteria: * Acute lymphoid leukemia: * 25% blasts in the bone marrow (M3 bone marrow), excluding patients with known central nervous system (CNS) disease * Acute myeloid leukemia according to FAB classification * ≥ 5 % blasts in the bone marrow (M2/M3 bone marrow); excluding patients with known CNS disease * Rhabdoid tumors: * To be eligible for enrollment in the rhabdoid tumors stratum, the patient must have a solid tumor where the institutional pathological evaluation of the tumor at initial diagnosis or relapse has confirmed: * Morphology and immunophenotypic panel consistent with rhabdoid tumor (required) * Loss of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 (INI1) confirmed by immunohistochemistry, or * Molecular confirmation of tumor-specific bi-allelic INI1 loss/mutation if INI1 immunohistochemistry is not available; note that molecular confirmation of tumor-specific bi-allelic INI1 loss/mutation is encouraged in cases where INI1 immunohistochemistry is equivocal * Patients must have a Lansky or Karnofsky performance status score of ≥ 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients ≤ 16 years of age; Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment * Myelosuppressive chemotherapy: * Solid tumors: * Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea) * Leukemia: * Patients with leukemia who relapse while receiving standard maintenance therapy will not be required to have a waiting period before enrollment onto this study * Patients who relapse while they are not receiving standard maintenance therapy must have completely recovered from all acute toxic effects of chemotherapy, immunotherapy or radiotherapy prior to study enrollment; at least 14 days must have elapsed since the completion of cytotoxic therapy, with the exception of hydroxyurea * Note: cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of MLN8237 * At least 7 days must have elapsed since the completion of therapy with a growth factor; at least 14 days must have elapsed after receiving pegfilgrastim * At least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur * At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody * ≥ 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); ≥ 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; ≥ 6 months must have elapsed if prior craniospinal XRT was received, if ≥ 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; ≥ 6 weeks must have elapsed if other substantial bone marrow irradiation was given * No evidence of active graft vs. host disease and ≥ 3 months must have elapsed since transplant * For patients with solid tumors without bone marrow involvement: * Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3 * Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) * Hemoglobin \> 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) * For patients with solid tumors and known bone marrow metastatic disease: * Peripheral absolute neutrophil count (ANC) ≥ 750/mm\^3 * Platelet count ≥ 50,000/mm\^3 * Hemoglobin ≥ 8.0 g/dL * Transfusions are permitted to meet both the platelet and hemoglobin criteria; patients must not be known to be refractory to red blood cell or platelet transfusions * Patients with leukemia must not be known to be refractory to red blood cell or platelet transfusions * Creatinine clearance or radioisotope glomerular filtration rate (GFR) 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * 1 to \< 2 years: 0.6 * 2 to \< 6 years: 0.8 * 6 to \< 10 years: 1 * 10 to \< 13 years: 1.2 * 13 to \< 16 years: 1.5 (male), 1.4 (female) * \>= 16 years: 1.7 (male), 1.4 (female) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age * Serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) ≤ 5.0 x ULN for age (≤ 225 U/L); for the purpose of this study, the ULN for SGPT is 45 U/L * Serum albumin ≥ 2 g/dL * All patients and/or their parents or legal guardians must sign a written informed consent Exclusion Criteria: * Patients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy; breastfeeding women are excluded * Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim) * Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible * Patients who are currently receiving another investigational drug are not eligible * Patients who are currently receiving other anti-cancer agents are not eligible * Use of daily benzodiazepine therapy excludes a patient from being eligible because of the potential benzodiazepine-like effects of MLN8237 * Patients who are currently receiving digoxin, cyclosporine, tacrolimus, or sirolimus are not eligible * Patients who are unable to swallow tablets are not eligible * Patients who have an uncontrolled infection are not eligible * Leukemia patients with CNS disease are not eligible * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
healthy Volunteers
false
maximum Age
21 Years
minimum Age
1 Year
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm I (neuroblastoma- measurable)
    type
    EXPERIMENTAL
  2. description
    Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm II (Neuroblastoma- MIBG evaluable)
    type
    EXPERIMENTAL
  3. description
    Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm III (rhabdomyosarcoma)
    type
    EXPERIMENTAL
  4. description
    Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm IV (osteosarcoma)
    type
    EXPERIMENTAL
  5. description
    Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm V (Ewing sarcoma/peripheral PNET)
    type
    EXPERIMENTAL
  6. description
    Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm VI (non-RMS soft tissue sarcoma)
    type
    EXPERIMENTAL
  7. description
    Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm VII (hepatoblastoma)
    type
    EXPERIMENTAL
  8. description
    Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm VIII (malignant germ cell tumor)
    type
    EXPERIMENTAL
  9. description
    Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm IX (Wilms tumor)
    type
    EXPERIMENTAL
  10. description
    Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm X (acute lymphoblastic leukemia)
    type
    EXPERIMENTAL
  11. description
    Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm XI (acute myelogenous leukemia)
    type
    EXPERIMENTAL
  12. description
    Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Alisertib
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm XII (rhabdoid malignancy)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I (neuroblastoma- measurable)
    2. Arm II (Neuroblastoma- MIBG evaluable)
    3. Arm III (rhabdomyosarcoma)
    4. Arm IV (osteosarcoma)
    5. Arm IX (Wilms tumor)
    6. Arm V (Ewing sarcoma/peripheral PNET)
    7. Arm VI (non-RMS soft tissue sarcoma)
    8. Arm VII (hepatoblastoma)
    9. Arm VIII (malignant germ cell tumor)
    10. Arm X (acute lymphoblastic leukemia)
    11. Arm XI (acute myelogenous leukemia)
    12. Arm XII (rhabdoid malignancy)
    description
    Given orally
    name
    Alisertib
    other Names
    1. Aurora A Kinase Inhibitor MLN8237
    2. MLN-8237
    3. MLN8237
    type
    DRUG
  2. arm Group Labels
    1. Arm I (neuroblastoma- measurable)
    2. Arm II (Neuroblastoma- MIBG evaluable)
    3. Arm III (rhabdomyosarcoma)
    4. Arm IV (osteosarcoma)
    5. Arm IX (Wilms tumor)
    6. Arm V (Ewing sarcoma/peripheral PNET)
    7. Arm VI (non-RMS soft tissue sarcoma)
    8. Arm VII (hepatoblastoma)
    9. Arm VIII (malignant germ cell tumor)
    10. Arm X (acute lymphoblastic leukemia)
    11. Arm XI (acute myelogenous leukemia)
    12. Arm XII (rhabdoid malignancy)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  3. arm Group Labels
    1. Arm I (neuroblastoma- measurable)
    2. Arm II (Neuroblastoma- MIBG evaluable)
    3. Arm III (rhabdomyosarcoma)
    4. Arm IV (osteosarcoma)
    5. Arm IX (Wilms tumor)
    6. Arm V (Ewing sarcoma/peripheral PNET)
    7. Arm VI (non-RMS soft tissue sarcoma)
    8. Arm VII (hepatoblastoma)
    9. Arm VIII (malignant germ cell tumor)
    10. Arm X (acute lymphoblastic leukemia)
    11. Arm XI (acute myelogenous leukemia)
    12. Arm XII (rhabdoid malignancy)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
118
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    For patients with recurrent solid tumors a patient who experienced a complete or partial response according to RECIST version 1.1 criteria is considered a responder. For patients with recurrent acute lymphoblastic leukemia a patient who experiences a bone marrow evaluation with \< 5% blast cells on morphological evaluation of bone marrow will be considered a responder. For patients with recurrent acute myelogenous leukemia a patient who experiences a complete remission or complete remission with partial recovery of platelet count according to the AML International Working Group Criteria will be considered a responder.
    measure
    Number of Participants With Overall Response
    time Frame
    From first dose of alisertib through 6 cycles of protocol therapy or until removal from protocol therapy whichever occurred first.
secondary Outcomes
  1. description
    The number of patient-cycles in which the adverse event considered grade 3 or higher AE according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 considered by the treating physician to be possibly, probably or definitely related to alisertib.
    measure
    Number of Patients Cycles With Grade 3 or Higher Adverse Event
    time Frame
    Up to 24 months
  2. description
    Serum concentration of alisertib prior to the first day of administration in nanograms/milliliter.
    measure
    Serum Concentration of Alisertib Prior to the First Day of Administration
    time Frame
    day 1 of protocol therapy
  3. description
    Serum concentration of alisertib on the first day of administration one hour after administration in nanograms/milliliter.
    measure
    Serum Concentration of Alisertib on the First Day of Administration One Hour After Administration
    time Frame
    day 1 of protocol therapy
  4. description
    Serum concentration of alisertib on the first day of administration three hours after administration in nanograms/milliliter.
    measure
    Serum Concentration of Alisertib on the First Day of Administration Three Hours After Administration
    time Frame
    day 1 of protocol therapy
  5. description
    Serum concentration of alisertib on the first day of administration six hours after administration in nanograms/milliliter.
    measure
    Serum Concentration of Alisertib on the First Day of Administration Six Hours After Administration
    time Frame
    day 1 of protocol therapy
  6. description
    Serum concentration of alisertib on the fourth day of administration prior to the administration of the day 4 dose in nanograms/milliliter.
    measure
    Serum Concentration of Alisertib on the Fourth Day of Administration Prior to the Administration of the Day 4 Dose
    time Frame
    day 4 of protocol therapy
  7. description
    Serum concentration of alisertib on the seventh day of administration prior to the administration of the day 7 dose in nanograms/milliliter.
    measure
    Serum Concentration of Alisertib on the Seventh Day of Administration Prior to the Administration of the Day 7 Dose.
    time Frame
    day 7 of protocol therapy
Full study description
brief Summary
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
detailed Description
PRIMARY OBJECTIVE: I. To determine the objective response rate to MLN8237 (alisertib) in children with relapsed or refractory solid tumors and leukemias, administered once daily for 7 days every 21 days. SECONDARY OBJECTIVES: I. To further define and describe the toxicities of MLN8237 administered on this schedule. II. To further characterize the pharmacokinetics of MLN8237 in children with refractory cancer. III. To evaluate aurora A kinase expression using immunohistochemistry in solid tumors and leukemic blasts from tissue obtained at diagnosis and, if available, at relapse. IV. To explore the relationship between polymorphic variations in the UDP-glucuronosyltransferase gene UGT1A1 and exposure to MLN8237, and to assess 2 common polymorphic variants in the aurora A kinase gene, Phe31Ile and Val57Ile. OUTLINE: This is a multicenter study. Patients are stratified according to type of tumor (measurable neuroblastoma vs neuroblastoma with metaiodobenzylguanidine \[MIBG\]-positive lesions vs osteosarcoma vs Ewing sarcoma/primitive neuroectodermal tumor \[PNET\] vs rhabdosarcoma vs non-rhabdomyosarcoma \[RMS\] soft tissue sarcoma vs hepatoblastoma vs malignant germ cell tumor vs Wilms tumor vs acute myeloid leukemia \[AML\] vs acute lymphoblastic leukemia \[ALL\] vs rhabdoid tumors). ARM I (NEUROBLASTOMA- MEASURABLE): Patients receive alisertib orally (PO) once daily (QD) on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM II (NEUROBLASTOMA-MIBG EVALUABLE): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM III (RHABDOMYOSARCOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM IV (OSTEOSARCOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM V (EWING SARCOMA/ PERIPHERAL PNET): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM VI (NON-RMS SOFT TISSUE SARCOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM VII (HEPATOBLASTOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM VIII (MALIGNANT GERM CELL TUMOR): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM IX (WILMS TUMOR): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM X (ACUTE LYMPHOBLASTIC LEUKEMIA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM XI (ACUTE MYELOGENOUS LEUKEMIA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. ARM XII (RHABDOID MALIGNANCY): Patients receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Plasma samples are collected from all patients at baseline and periodically during course 1 for pharmacokinetic and other studies. After completion of study therapy, patients are followed up for 5 years.
Source references
references
  1. citation
    Zhou X, Mould DR, Yuan Y, Fox E, Greengard E, Faller DV, Venkatakrishnan K. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. J Clin Pharmacol. 2022 Feb;62(2):206-219. doi: 10.1002/jcph.1958. Epub 2022 Jan 15.
    pmid
    34435684
    type
    DERIVED
  2. citation
    Mosse YP, Fox E, Teachey DT, Reid JM, Safgren SL, Carol H, Lock RB, Houghton PJ, Smith MA, Hall D, Barkauskas DA, Krailo M, Voss SD, Berg SL, Blaney SM, Weigel BJ. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 Jun 1;25(11):3229-3238. doi: 10.1158/1078-0432.CCR-18-2675. Epub 2019 Feb 18.
    pmid
    30777875
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-dcb67db1199d661c8d60
      requested nct id
      NCT01154816
      primary nct id
      NCT01154816
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      payload sha256
      77cb058922d4f9dc956217d08bcd2f05aa5f9c855c98b30489045aadf1753785
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-dcb67db1199d661c8d60
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01154816
      occurrences
      1. context exact
        NCT01154816
        end
        11
        exact text
        NCT01154816
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Kidney Tumors
      query disease state id
      ds-childhood-kidney-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-kidney-tumors-000.json
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      source json pointer
      /studies/2/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e18100b86118c405135e4c5656609fbd3a839c33bcba2aaaa929cd785c5eded2

    Preserved source evidence · Not medical advice